Substrate reduction therapy in the infantile form of Tay-Sachs disease.

Substrate reduction therapy in the infantile form of Tay-Sachs disease.

Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two...

Full description

Bibliographic Details
Main Authors:	Bembi, B, Marchetti, F, Guerci, V, Ciana, G, Addobbati, R, Grasso, D, Barone, R, Cariati, R, Fernandez-Guillen, L, Butters, T, Pittis, MG
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Tay-Sachs disease
by: Carlos Andrés Gualdrón-Frías, et al.
Published: (2019-07-01)

An inducible mouse model of late onset Tay-Sachs disease.
by: Jeyakumar, M, et al.
Published: (2002)

Prenatal Diagnosis Of Tay-Sachs Disease
by: Özgür Özyüncü, et al.
Published: (2010-04-01)

Therapeutic Strategies For Tay-Sachs Disease
by: Jaqueline A. Picache, et al.
Published: (2022-07-01)

New Approaches to Tay-Sachs Disease Therapy
by: Valeriya V. Solovyeva, et al.
Published: (2018-11-01)

Doença de Tay-Sachs: relato de caso
by: Pérola Grupenmacher Iankilevich, et al.
Published: (2023-04-01)

Testing fate: Tay-Sachs disease and the right to be responsible
by: Christie Sillo
Published: (2018-01-01)

Tay-Sachs disease: current perspectives from Australia
by: Lew RM, et al.
Published: (2015-01-01)

Characterization of inducible models of Tay-Sachs and related disease.
by: Timothy J Sargeant, et al.
Published: (2012-09-01)

Report of two Cases of Tay–Sachs in Children of a Single Family
by: N Sharifi, et al.
Published: (2019-07-01)

Preparation of radioactive Tay-Sachs ganglioside labeled in the sialic acid moiety
by: E.H. Kolodny, et al.
Published: (1970-03-01)

Neurodegeneration with progressive dystonia: Juvenile-onset Tay–Sachs disease
by: Jasmine Kaur, et al.
Published: (2022-01-01)

Abnormal gangliosides in Tay-Sachs disease, Niemann-Pick's disease, and gargoylism
by: D.A. Booth, et al.
Published: (1966-05-01)

Expanding the spectrum of HEXA mutations in Indian patients with Tay–Sachs disease
by: Jayesh Sheth, et al.
Published: (2014-01-01)

Moléstia de Tay-sachs: A Propósito de três casos
by: Oswaedo Freitas Juijao, et al.
Published: (1944-12-01)

Doença de Tay-Sachs em criança de raça negra
by: Sérgio Rosemberg, et al.
Published: (1970-12-01)

Biochemical and mutational analyses of HEXA in a cohort of Egyptian patients with infantile Tay-Sachs disease. Expansion of the mutation spectrum
by: Doaa M. A. Ibrahim, et al.
Published: (2023-03-01)

Nursing Care Plan for Patients with Tay–Sachs—A Rare Paediatric Disease
by: Jonathan Cortés-Martín, et al.
Published: (2023-08-01)

Autophagic flux is impaired in the brain tissue of Tay-Sachs disease mouse model.
by: Tugce Sengul, et al.
Published: (2023-01-01)

Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease
by: Mylinh Vu, et al.
Published: (2018-09-01)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
by: Rountree, J, et al.
Published: (2009)

Efficient and precise generation of Tay–Sachs disease model in rabbit by prime editing system
by: Yuqiang Qian, et al.
Published: (2021-07-01)

Haematopoietic stem cell transplantation arrests the progression of neurodegenerative disease in late-onset Tay-Sachs disease
by: Stepien, K, et al.
Published: (2017)

Generation of HEXA-deficient hiPSCs from fibroblasts of a Tay-Sachs disease patient
by: Zhong Liu, et al.
Published: (2016-09-01)

Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases
by: Nicole Lyn, et al.
Published: (2020-04-01)

Novel HEXA variants in Korean children with Tay–Sachs disease with regression of neurodevelopment from infancy
by: Ji Hong Park, et al.
Published: (2021-06-01)

Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
by: Takashi Kodama, et al.
Published: (2011-01-01)

Neuraminidase-1 contributes significantly to the degradation of neuronal B-series gangliosides but not to the bypass of the catabolic block in Tay–Sachs mouse models
by: Z.K. Timur, et al.
Published: (2015-09-01)

The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program
by: Roberto Rozenberg, et al.

Telemedicine and GM-2 gangliosidosis (Tay–Sachs) disease – A new savior on the horizon during COVID-19 pandemic
by: Rohini Grover, et al.
Published: (2021-01-01)

Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α
by: Sumita Raha, et al.
Published: (2023-12-01)

sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
by: Manuel González-Cuesta, et al.
Published: (2022-12-01)

GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease
by: Seçil Akyıldız Demir, et al.
Published: (2020-09-01)

A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)
by: Elin Haf Davies, et al.
Published: (2020-08-01)

Analysis of Brain Lipids in the Early-Onset Tay–Sachs Disease Mouse Model With the Combined Deficiency of β-Hexosaminidase A and Neuraminidase 3
by: Melike Can, et al.
Published: (2022-08-01)

Screening for Tay‐Sachs disease carriers by full‐exon sequencing with novel variant interpretation outperforms enzyme testing in a pan‐ethnic cohort
by: Alana C. Cecchi, et al.
Published: (2019-08-01)

Substrate reduction therapy
by: Platt, F, et al.
Published: (2007)

Investigating Immune Responses to the scAAV9-<i>HEXM</i> Gene Therapy Treatment in Tay–Sachs Disease and Sandhoff Disease Mouse Models
by: Shalini Kot, et al.
Published: (2021-06-01)

Eng Tay : the exhibition /
by: Joseph, Rahel, et al.
Published: (2009)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
by: Platt, F, et al.
Published: (2003)